We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
How Applicable Is the Single-Dose AMBITION Regimen for Human Immunodeficiency Virus–Associated Cryptococcal Meningitis to High-Income Settings?
- Authors
Harrison, Thomas S; Lawrence, David S; Mwandumba, Henry C; Boulware, David R; Hosseinipour, Mina C; Lortholary, Olivier; Meintjes, Graeme; Mosepele, Mosepele; Jarvis, Joseph N
- Abstract
The AmBisome Therapy Induction Optimization (AMBITION-cm) trial, conducted in eastern and southern Africa, showed that a single, high dose (10 mg/kg) of liposomal amphotericin B, given with an oral backbone of fluconazole and flucytosine, was noninferior to the World Health Organization (WHO)–recommended regimen of 7 days of amphotericin B deoxycholate plus flucytosine for treatment of human immunodeficiency virus (HIV)–associated cryptococcal meningitis and has been incorporated into WHO treatment guidelines. We believe that the trial also has important implications for the treatment of HIV-associated cryptococcal meningitis in high-income settings. We advance the arguments, supported by evidence where available, that the AMBITION-cm trial regimen is likely to be as fungicidal as the currently recommended 14-day liposomal amphotericin–based treatments, better tolerated with fewer adverse effects, and confer significant economic and practical benefits and, therefore, should be included as a treatment option in guidance for HIV-associated cryptococcal treatment in high-income settings.
- Subjects
SOUTHERN Africa; EASTERN Africa; WORLD Health Organization; AMPHOTERICIN B; DEVELOPED countries; HETEROCYCLIC compounds; MEDICAL protocols; CRYPTOCOCCUS neoformans; MENINGITIS; FLUCONAZOLE; HIV
- Publication
Clinical Infectious Diseases, 2023, Vol 76, Issue 5, p944
- ISSN
1058-4838
- Publication type
Article
- DOI
10.1093/cid/ciac792